Analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for Sage Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Leerink Partnrs analyst M.
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.
10d
Zacks.com on MSNBiogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance DisappointsBiogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate ...
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...
Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook disappointed due ...
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
H.C. Wainwright lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps a Neutral rating on the shares. The ...
Our Chief Operating Officer, Chris Benecchi, will provide an update on the ongoing commercialization of ZURZUVAE and key financial results. Our Chief Medical Officer, Laura Gault, will then provide a ...
Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results